Dr Reddy's Labs

Why is Dr Reddys Laboratories Ltd falling/rising?

As of 25-Jun, Dr Reddys Laboratories Ltd's stock price has risen to 1,350.00, reflecting a 1.63% increase. This growth is driven by strong performance against the benchmark Sensex, high investor interest, and positive trading trends, alongside solid fundamentals and management efficiency.

As of 25-Jun, Dr Reddys Laboratories Ltd is experiencing a rise in its stock price, currently at 1,350.00, which reflects an increase of 21.65 or 1.63%. This upward movement can be attributed to several factors. Over the past week, the stock has outperformed the benchmark Sensex, gaining 6.48% compared to a decline of 0.40% in the index. Additionally, the stock has shown a strong performance today, outperforming its sector by 1.99% and achieving a consecutive gain over the last five days, with a total return of 6.56% during this period.<BR><BR>The stock is also close to its 52-week high, just 1.85% away from the peak of Rs 1376, and it reached an intraday high of Rs 1362.65, indicating strong investor interest. The trading activity reflects rising investor participation, with a delivery volume of 13.56 lacs on 24 June, which is a significant increase of 91.57% compared to the five-day average. Furthermore, Dr Reddy's Laboratories is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, suggesting a positive trend in its price movement.<BR><BR>The company also benefits from high management efficiency, being net-debt free, and demonstrating healthy long-term growth with net sales increasing at an annual rate of 12.09%. High institutional holdings at 63.8% indicate confidence from larger investors who typically have more resources to analyze the company's fundamentals. These factors collectively contribute to the stock's rising price.

Which are the latest news on Dr Reddy's Labs?

How big is Dr Reddy's Labs?

As of 10th June, Dr Reddy's Laboratories Ltd has a market capitalization of 106,370.00 Cr and reported net sales of 33,700.20 Cr and net profit of 4,196.00 Cr over the latest four quarters.

As of 10th June, <BR><BR>Market Cap: Dr Reddys Laboratories Ltd has a market capitalization of 106,370.00 Cr, classified as Large Cap.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 33,700.20 Cr, while the sum of Net Profit for the same period is 4,196.00 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the balance sheet is March 2025. Shareholder's Funds are valued at 33,549.60 Cr, and Total Assets amount to 47,594.10 Cr.

Who are in the management team of Dr Reddy's Labs?

The management team of Dr Reddy's Labs includes G V Prasad (Co-Chairman & Managing Director), K Satish Reddy (Executive Chairman), and several independent directors such as Kalpana Morparia and Leo Puri, among others, who guide the company's strategic direction and ensure regulatory compliance.

The management team of Dr Reddy's Labs includes the following key members:<BR><BR>1. G V Prasad - Co-Chairman & Managing Director<BR>2. K Satish Reddy - Executive Chairman<BR>3. Kalpana Morparia - Independent Director<BR>4. Shikha Sanjaya Sharma - Independent Director<BR>5. Leo Puri - Independent Director<BR>6. K P Krishnan - Independent Director<BR>7. Pennv Wan - Independent Director<BR>8. K Randhir Singh - Company Secretary & Compliance Officer<BR>9. Arun M. Kumar - Independent Director<BR>10. Claudio Albrecht - Independent Director<BR><BR>This team plays a crucial role in guiding the company's strategic direction and ensuring compliance with regulatory standards.

Who are the peers of the Dr Reddy's Labs?

Dr Reddy's Labs' peers include Sun Pharma, Divi's Lab, Torrent Pharma, Cipla, Zydus Lifesciences, Lupin, Mankind Pharma, Aurobindo Pharma, Laurus Labs, and Biocon. Torrent Pharma has the highest 1-year return at 42.80%, while Dr Reddy's Labs has a return of -5.48%.

Peers: The peers of Dr Reddy's Labs are Sun Pharma.Inds., Divi's Lab., Torrent Pharma, Cipla, Zydus Lifesci., Lupin, Mankind Pharma, Aurobindo Pharma, Laurus Labs, and Biocon.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Divi's Lab., Torrent Pharma, Cipla, Zydus Lifesci., Lupin, Mankind Pharma, Laurus Labs, and the rest. Good growth is noted at Sun Pharma.Inds., Zydus Lifesci., Lupin, Mankind Pharma, while Below Average growth is found at Divi's Lab., Cipla, Aurobindo Pharma, Laurus Labs, and the rest. Excellent capital structure is seen at Sun Pharma.Inds., Divi's Lab., Cipla, Zydus Lifesci., Mankind Pharma, Aurobindo Pharma, while Average capital structure is found at Laurus Labs and Below Average at Biocon.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Torrent Pharma at 42.80%, while the lowest is Cipla at -8.87%. Dr Reddy's Labs has a 1-year return of -5.48%, which is better than Cipla but worse than Torrent Pharma. Additionally, the six-month return is negative for Cipla and Dr Reddy's Labs.

What does Dr Reddy's Labs do?

Dr Reddy's Laboratories Limited is a global pharmaceutical company focused on providing affordable and innovative medicines. As of March 2026, it reported net sales of ₹7,546 Cr and a net profit of ₹221 Cr, with a market cap of ₹106,370 Cr.

Overview: <BR>Dr Reddy's Laboratories Limited (DRL) is an integrated global pharmaceutical company committed to providing affordable and innovative medicines in the Pharmaceuticals & Biotechnology industry, categorized as a Large Cap.<BR><BR>History: <BR>Dr Reddy's Laboratories was incorporated in 1984. The latest quarterly results reported net sales and profit for the period ending March 2026.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 7,546 Cr (Quarterly Results - Mar 2026) <BR>Most recent Net Profit: 221 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 106,370 Cr (Large Cap)<BR><BR>Key Metrics: <BR>P/E: 25.00 <BR>Industry P/E: 34 <BR>Dividend Yield: 0.63% <BR>Debt-Equity: 0.01 <BR>Return on Equity: 11.07% <BR>Price to Book: 2.79 <BR><BR>Contact Details: <BR>Address: 8-2-337 Road No 3, Banjara Hills Hyderabad Telangana : 500034 <BR>Tel: 91-40-49002900 <BR>Email: shares@drreddys.com <BR>Website: http://www.drreddys.com

Are Dr Reddys Laboratories Ltd latest results good or bad?

Dr. Reddy's Laboratories Ltd. reported disappointing Q4 FY26 results, with a net profit decline of 86.14% and an 11.51% drop in revenue, marking significant operational challenges and raising concerns about business sustainability. The outlook appears negative, prompting caution for investors.

Dr. Reddy's Laboratories Ltd. has reported disappointing results for Q4 FY26, indicating a significant downturn in its financial performance. The company's net profit collapsed by 86.14% year-on-year to ₹220.90 crores, and revenue fell by 11.51% year-on-year to ₹7,546.40 crores. This marks the first time in years that Dr. Reddy's has experienced a double-digit revenue contraction, raising concerns about its business sustainability.<BR><BR>Operating margins also suffered dramatically, plummeting to 5.09% from 23.49% a year ago, which is the lowest in recent history. The decline in operating profit before depreciation, interest, tax, and other income (PBDIT) was staggering, dropping 80.85% year-on-year. The company's reliance on non-operating income to maintain profitability is alarming, as this income accounted for a significant portion of profit before tax.<BR><BR>While Dr. Reddy's had shown strong performance in the earlier quarters of FY26, the Q4 results overshadow these achievements and highlight serious operational challenges. The financial metrics indicate a critical need for management to address the issues affecting margins and revenue. Given these results, the outlook appears negative, and investors may need to exercise caution moving forward.

Should I buy, sell or hold Dr Reddys Laboratories Ltd?

How has been the historical performance of Dr Reddy's Labs?

Dr Reddy's Labs has shown consistent growth from Mar'20 to Mar'25, with net sales increasing from 17,517 Cr to 32,643.90 Cr and profit after tax rising from 1,969.90 Cr to 5,703.50 Cr. The company has maintained positive cash flow and expanded its total assets significantly, reflecting strong financial health.

Answer:<BR>The historical performance of Dr Reddy's Labs shows a consistent growth trajectory in net sales, with figures rising from 17,517.00 Cr in Mar'20 to 32,643.90 Cr in Mar'25. Total operating income has mirrored this trend, increasing from 17,517.00 Cr in Mar'20 to 32,643.90 Cr in Mar'25. Operating profit (PBDIT) has also seen significant growth, climbing from 3,091.00 Cr in Mar'20 to 9,644.40 Cr in Mar'25, although the operating profit margin has fluctuated, peaking at 28.42% in Mar'24 before dropping to 26.26% in Mar'25. Profit before tax has increased from 1,829.60 Cr in Mar'20 to 7,657.80 Cr in Mar'25, while profit after tax has risen from 1,969.90 Cr to 5,703.50 Cr over the same period. The company's total assets have grown from 22,005.40 Cr in Mar'20 to 47,594.10 Cr in Mar'25, reflecting a strong balance sheet, while total liabilities have also increased, from 22,005.40 Cr to 47,594.10 Cr. Cash flow from operating activities has shown a positive trend, increasing from 2,984.00 Cr in Mar'20 to 4,642.00 Cr in Mar'25, contributing to a net cash inflow of 748.00 Cr in Mar'25.<BR><BR>Breakdown:<BR>Dr Reddy's Labs has demonstrated robust growth in net sales, which rose from 17,517.00 Cr in Mar'20 to 32,643.90 Cr in Mar'25, indicating a strong demand for its products. The total operating income followed suit, reflecting the same upward trend. Operating profit (PBDIT) has significantly increased, reaching 9,644.40 Cr in Mar'25, although the operating profit margin experienced some volatility. Profit before tax surged to 7,657.80 Cr, while profit after tax reached 5,703.50 Cr, showcasing the company's improving profitability. The total assets of Dr Reddy's Labs expanded considerably, reflecting its growth strategy, while total liabilities also increased, indicating a corresponding rise in financial obligations. The cash flow from operating activities has remained positive, contributing to a net cash inflow, which further underscores the company's solid financial health and operational efficiency.

Is Dr Reddy's Labs technically bullish or bearish?

As of November 28, 2025, Dr Reddy's Labs shows a mildly bullish trend based on daily moving averages and weekly Dow Theory, despite mixed signals from weekly MACD and KST indicators.

As of 28 November 2025, the technical trend for Dr Reddy's Labs has changed from sideways to mildly bullish. The daily moving averages indicate a bullish stance, while the weekly MACD and KST are bearish, suggesting mixed signals. The weekly Dow Theory shows a mildly bullish trend, but the monthly indicators remain mostly bearish or neutral. Overall, the current technical stance is mildly bullish, driven primarily by the daily moving averages and the weekly Dow Theory, despite the bearish signals from MACD and KST on the weekly time frame.

Is Dr Reddy's Labs overvalued or undervalued?

As of October 27, 2025, Dr Reddy's Labs is fairly valued with a PE ratio of 18.57, lower than its peers like Sun Pharma and Divi's Lab, despite recent underperformance compared to the Sensex.

As of 27 October 2025, Dr Reddy's Labs has moved from a very attractive to an attractive valuation grade. The company is currently considered fairly valued. Key ratios include a PE ratio of 18.57, an EV to EBITDA ratio of 11.31, and a Price to Book Value of 0.30, which indicate a reasonable valuation compared to its peers.<BR><BR>In comparison to its peers, Dr Reddy's Labs has a lower PE ratio than Sun Pharma (35.43) and Divi's Lab (74.62), both of which are classified as expensive. Additionally, it is on par with Cipla (PE of 23.74) and Zydus Lifesciences (PE of 21.52), which are also attractive. Despite a recent underperformance relative to the Sensex over the past year, where Dr Reddy's returned -1.40% compared to the Sensex's 6.77%, the valuation metrics suggest that the stock is currently fairly valued in the market.

Who are the top shareholders of the Dr Reddy's Labs?

The top shareholders of Dr Reddy's Labs include promoter G V Prasad with 11.52%, J P Morgan Chase Bank Na as the largest public shareholder at 11.54%, mutual funds holding 12.89%, foreign institutional investors at 25.75%, and individual investors with approximately 8.2%.

The top shareholders of Dr Reddy's Labs include several key players. The majority shareholders are the promoters, with G V Prasad being the promoter with the highest holding at 11.52%. In the public domain, J P Morgan Chase Bank Na holds a significant stake of 11.54%, making it the highest public shareholder. Additionally, mutual funds collectively hold 12.89% through 38 schemes, while foreign institutional investors (FIIs) account for 25.75% with 799 FIIs involved. Individual investors hold around 8.2% of the shares.

When is the next results date for Dr Reddy's Labs?

No Upcoming Board Meetings

What is the bonus history of the Dr Reddy's Labs?

Dr. Reddy's Laboratories issued a 1:1 bonus on August 28, 2006, allowing shareholders to double their holdings by receiving an additional share for each share owned, with the record date set for August 29, 2006.

Dr. Reddy's Laboratories has a bonus history that includes a notable 1:1 bonus issue announced on August 28, 2006. The record date for this bonus was August 29, 2006. This means that for every share held, shareholders received an additional share, effectively doubling their holdings at that time. If you have any more questions about the company or its financials, feel free to ask!

Has Dr Reddy's Labs declared dividend?

Yes, Dr Reddy's Laboratories has declared an 800% dividend, amounting to ₹40 per share, with an ex-date of July 16, 2024. The company has demonstrated strong total returns across various periods, with a total return of 15.2% over the past year.

Dr Reddy's Laboratories Ltd has declared an 800% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 800%<BR>- Amount per share: 40<BR>- Ex-date: 16 Jul 24<BR><BR>Dividend Yield: 0.62%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was 5.26%, with no dividend return, resulting in a total return of 5.26%.<BR><BR>Over the past year, the price return was 11.89%, the dividend return was 3.31%, leading to a total return of 15.2%.<BR><BR>In the 2-year period, the price return was 42.35%, the dividend return was 8.21%, culminating in a total return of 50.56%.<BR><BR>For the last 3 years, the price return was 53.12%, with a dividend return of 12.94%, resulting in a total return of 66.06%.<BR><BR>In the 4-year timeframe, the price return was 25.6%, the dividend return was 12.49%, giving a total return of 38.09%.<BR><BR>Lastly, over the past 5 years, the price return was 63.89%, with a dividend return of 20.41%, leading to a total return of 84.3%.<BR><BR>Overall, Dr Reddy's Laboratories has declared a substantial dividend while also showing strong total returns across multiple periods, indicating a positive financial performance for the company.